The 6th Meeting of the European Society of Oncological Urology (ESOU) will be held in Istanbul, Turkey, from 16 to 18 January 2009, with organisers presenting the latest updates on treatment strategies to onco-urology specialists.
With the fast-changing developments in onco-urological treatment strategies, the ESOU aims to provide urologists, gynaecologists, oncologists, scientists and researchers the opportunity to explore the various options that will enable cancer specialists to identify optimal treatment approaches.
"The ESOU is and intends to remain - one of the most important platforms of scientific information exchange among experts as well as professionals interested in the field. It will continue to serve as a key opinion leader and promote the dissemination of high-quality uro-oncological scientific information, in order to increase the quality of medical service," said ESOU Chairman Prof. Vincent Ravery (Paris, France).
The most common malignancies such as prostate cancer (PCa), renal cell carcinoma and bladder cancer were the focus of last year's meeting in Berlin. Apart from these conditions, testis cancer will be another highlight of the forthcoming meeting in Istanbul.
Prof. Levent Trkeri (Istanbul, Turkey), ESOU board member and local organiser said: "On Friday, 16 January, an interesting pro-contra debate is organised entitled 'Should hormones (adjuvant/neo-adjuvant) be dedicated to radiotherapy and abandoned in patients to be treated with surgery?' Furthermore, the lecture by Prof. Theo de Reijke of the European Organisation on the Research and Treatment of Cancer-Genitourinary Group (Update on the recent data retrieved from EORTC GU group studies) deserves attention."
The introduction of targeted therapies, which will be discussed during the sessions on renal cell carcinoma, meant a revolution in the field of oncology in general. These therapies appear to evolve into the mainstay of medical
|Contact: Lindy Brouwer|
European Association of Urology